Given the dose-related toxicity or side effect for VS-6063 or other FAK inhibitors (e.g., TAE-226), the inclusion of JQ1-type inhibitor should lower the IC50 of FAK inhibitors, thereby enhancing the effectiveness of VS-6063-based targeting in ovarian cancer. This evidence concerns the gene PTK2 and ovarian cancer.